Raymond James & Associates Relay Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 66,842 shares of RLAY stock, worth $442,494. This represents 0.0% of its overall portfolio holdings.
Number of Shares
66,842
Previous 36,977
80.77%
Holding current value
$442,494
Previous $241,000
96.27%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RLAY
# of Institutions
215Shares Held
168MCall Options Held
714KPut Options Held
14.9K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$185 Million1.1% of portfolio
-
Commodore Capital LP New York, NY17MShares$113 Million5.66% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct14.8MShares$97.8 Million0.15% of portfolio
-
Casdin Capital, LLC New York, NY11.3MShares$75.1 Million8.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$69.8 Million0.0% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $796M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...